Congratulations to Dr Matthew Lacorcia
News

February 2024

Congratulations to Dr Matthew Lacorcia

Matt has been awarded a JDRF Postdoctoral Fellowship for his work on developing an early diagnostic test for type 1 diabetes.

Congratulations to Professor André La Gerche
News

February 2024

Congratulations to Professor André La Gerche

Congratulations to André La Gerche on his promotion to Professor.

New early diagnostic test for Friedreich ataxia heart disease
News

January 2024

New early diagnostic test for Friedreich ataxia heart disease

Associate Professor Shiang (MAX) Lim has been awarded funding to work on the development of a new, non-invasive test to diagnose and monitor heart disease in people with a genetic condition that, up until now, has made diagnosis impossible.

Are elite athletes more at risk from heart disease?
News

December 2023

Are elite athletes more at risk from heart disease?

A landmark new study published in Circulation has found that certain genes in elite athletes could also be responsible for a higher risk of heart disease.

NHMRC recognises SVI’s research excellence
News

December 2023

NHMRC recognises SVI’s research excellence

Three of SVI's researchers have been awarded prestigious NHMRC Investigator Grants to tackle bone disease, heart disease and rare diseases. These grants are awarded Australia's highest achieving researchers.

New funding to tackle Australia’s toughest health problems
News

December 2023

New funding to tackle Australia’s toughest health problems

The NHMRC has awarded SVI researchers more than $7.7 million for research into cancer, liver disease, heart disease and type 2 diabetes.

New funding to tackle age-related bone disease
News

December 2023

New funding to tackle age-related bone disease

Prof Natalie Sims has been awarded a prestigious NHMRC Investigator Grant to better understand the causes of age-related bone fragility.

New hope for type 1 diabetes
News

December 2023

New hope for type 1 diabetes

An Australian world-first clinical trial published today in the New England Journal of Medicine, has shown that a commonly prescribed rheumatoid arthritis drug can preserve the body’s own insulin production and suppress the progression of type 1 diabetes (T1D) in those newly diagnosed with the condition.